PubMed · 8925336
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
M Bourel. 1996. [Cellular therapy].. https://pubmed.ncbi.nlm.nih.gov/8925336/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Approximately 310,000 Americans suffer from end-stage renal disease, with more than 70,000 new cases reported each year. Advances in immunosuppressive therapy for transplanted patients, in addition to the refined care of patients who are dependent on dialysis, have led to an improved survival for patients with renal failure. Structural, molecular, and pharmacologic developments continue to enhance the efficacy and safety of dialysis in the future. In addition, progressive improvements in the past 2 decades in organ transplantation, a greater insight into the immunobiology of graft rejection, and better surgical and medical management have resulted in improved outcomes. Although renal xenotransplantation is still in its early stages of development, additional research is leading this technology forward. Recent successes in harvesting and expanding renal cells in vitro and the development of biologically active synthetic materials allow for the creation of three-dimensional functioning renal units, which, in the future, may be applied ex vivo or in vivo for partial or full replacement of kidney function.
PURPOSE: To facilitate increased use of keratolimbal allograft transplantation (KLAL) for severe ocular surface disease (OSD) by informing clinicians and eye banks of differences in tissue requirements and preparation for the procedure and to describe the surgical technique of KLAL transplantation. METHODS: The protocol of the Minnesota Lions Eye Bank is described for procuring and preparing tissue for KLAL transplantation. The surgical technique is described in detail. RESULTS: Over the last several years, we have modified our eye-banking procedures as well as our surgical technique to improve the success of KLAL transplantation. CONCLUSION: KLAL transplantation for patients with severe ocular-surface disease is an important management option. Success is influenced by the ability to obtain appropriate tissue; this requires clinicians and eye banks to expand current procurement guidelines.
Explore the source record for details and available documents.